FORM 10-QSB

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                   QUARTERLY REPORT UNDER SECTION 13 OR 15 (d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934


For Quarter Ended September 30, 2002


Commission File Number 1-8635

                          AMERICAN MEDICAL ALERT CORP.
        (Exact Name of Small Business Issuer as Specified in its Charter)

New York                                                11-2571221
(State or other jurisdiction of                         (I.R.S. Employer
incorporation or organization)                          Identification Number)

                3265 Lawson Boulevard, Oceanside, New York 11572
                    (Address of principal executive offices)
                                   (Zip Code)

                                 (516) 536-5850
                (Issuer's telephone number, including area code)

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Securities  Exchange  Act of 1934  during the  preceding  12
months (or for such shorter period that the registrant was required to file such
reports),  and (2) has been subject to such filing  requirements for the past 90
days. Yes X No ___

Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the latest  practicable  date:  7,470,649 shares of $.01 par
value common stock as of November 8, 2002.

<PAGE>

                  AMERICAN MEDICAL ALERT CORP. AND SUBSIDIARIES


                                      INDEX


                                                                            PAGE

Part I.   Financial Information.

          Report of Independent Accountants                                  1

          Condensed Consolidated Balance Sheets for September 30, 2002
          and December 31, 2001                                              2

          Condensed Consolidated Statements of Income for the
          Nine Months Ended September 30, 2002 and 2001                      4

          Condensed Consolidated Statements of Income for the
          Three Months Ended September 30, 2002 and 2001                     5

          Condensed Consolidated Statements of Cash Flows for the
          Nine Months Ended September 30, 2002 and 2001                      6

          Notes to Condensed Consolidated Financial Statements               8

          Management's Discussion and Analysis of
          Financial Condition and Results of Operations.                     14

               Controls and Procedures                                       19

Part II. Other Information                                                   19

               Signatures                                                    22

               Certifications                                             23-24

<PAGE>

REPORT OF INDEPENDENT ACCOUNTANTS


Board of Directors and Shareholders
American Medical Alert Corp. and Subsidiaries
Oceanside, New York

We have reviewed the condensed  consolidated  balance sheet of American  Medical
Alert Corp. and Subsidiaries as of September 30, 2002 and the related  condensed
consolidated  statements of income for the  three-month  and nine-month  periods
ended  September  30, 2002 and 2001,  and cash flows for the nine  months  ended
September 30, 2002 and 2001. These financial  statements are the  responsibility
of the company's management.

We  conducted  our  reviews in  accordance  with  standards  established  by the
American  Institute  of  Certified  Public  Accountants.  A  review  of  interim
financial  information consists principally of applying analytical procedures to
financial  data and making  inquiries of persons  responsible  for financial and
accounting matters. It is substantially less in scope than an audit conducted in
accordance with generally accepted auditing standards, the objective of which is
the  expression  of an opinion  regarding the  financial  statements  taken as a
whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should
be made to the condensed consolidated financial statements referred to above for
them to be in conformity with accounting  principles  generally  accepted in the
United States of America.

We have  previously  audited,  in accordance with auditing  standards  generally
accepted in the United States of America,  the consolidated  balance sheet as of
December  31,  2001,  and  the  related   consolidated   statements  of  income,
shareholders'  equity  and cash  flows for the year then  ended  (not  presented
herein);  and in our report  dated March 14, 2002,  we expressed an  unqualified
opinion  on  those  consolidated  financial  statements.  In  our  opinion,  the
information set forth in the accompanying  condensed  consolidated balance sheet
as of December 31, 2001, is fairly stated, in all material respects, in relation
to the consolidated balance sheet from which it has been derived.


/s/Margolin, Winer & Evens LLP

Margolin, Winer & Evens LLP

November 8, 2002


                                      -1-

<PAGE>

                          PART I FINANCIAL INFORMATION

Item 1. Financial Statements.
        ---------------------

                  AMERICAN MEDICAL ALERT CORP. AND SUBSIDIARIES
                      CONDENSED CONSOLIDATED BALANCE SHEETS

                                     ASSETS

<TABLE>
<CAPTION>

                                                                           Sept. 30,2002
                                                                              (Unaudited)     Dec. 31,2001*
                                                                              -----------     -------------
<S>                                                                          <C>             <C>
CURRENT ASSETS
   Cash and cash equivalents                                                 $  1,079,612    $    818,696
   Marketable securities                                                        2,041,929             -
   Accounts and notes receivable
    (net of allowance for doubtful accounts of $527,500 and $417,500)           3,025,528       2,866,015
   Notes and other receivables                                                     91,767         276,594
   Inventory                                                                      325,706         171,283
   Prepaid and refundable taxes                                                    87,781         109,328
   Prepaid expenses and other current assets                                      265,307         123,987
   Deferred income taxes                                                          408,000         408,000
                                                                             ------------    ------------

   Total Current Assets                                                         7,325,630       4,773,903
                                                                             ------------    ------------
FIXED ASSETS
   (Net of accumulated depreciation and amortization)                           6,834,130       7,732,051
                                                                             ------------    ------------
OTHER ASSETS
   Long-term portion of notes receivable                                          150,850         162,918
   Intangible assets and deferred charges
      (net of accumulated amortization of $541,263 and $398,187)                  922,890         757,218
   Goodwill (net of accumulated amortization of $58,868)                          928,537         837,504
   Other assets                                                                   148,438         117,749
   Deferred income taxes                                                           50,000          50,000
                                                                             ------------    ------------
                                                                                2,200,715       1,925,389
                                                                             ------------    ------------
TOTAL ASSETS                                                                 $ 16,360,475    $ 14,431,343
                                                                             ============    ============
LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES:
   Current portion of long-term debt                                         $    314,917    $  1,345,616
   Accounts payable                                                               530,547         799,456
   Accrued expenses                                                               388,657         538,949
   Current portion of capital lease obligations                                   182,588         214,903
   Deferred revenue                                                                66,560         117,901
                                                                             ------------    ------------

     Total Current Liabilities                                                  1,483,269       3,016,825

DEFERRED INCOME TAX LIABILITY                                                     519,000         519,000
LONG-TERM DEBT                                                                  1,151,204         599,573
LONG-TERM PORTION OF CAPITAL LEASE OBLIGATIONS                                     54,726         180,065
PUT WARRANT OBLIGATION                                                            409,000         319,000
ACCRUED RENTAL OBLIGATION AND OTHER                                                53,500          61,466
                                                                             ------------    ------------

     TOTAL LIABILITIES                                                          3,670,699       4,695,929
                                                                             ------------    ------------


                                      -2-
<PAGE>

COMMITMENTS AND CONTINGENT LIABILITIES                                                -               -

SHAREHOLDERS' EQUITY
     Preferred stock, $ .01 par value - authorized, 1,000,000 shares; none
      issued and outstanding
     Common stock, $.01 par value - authorized, 20,000,000 shares;
      issued 7,470,649 and 6,498,545 shares in 2002 and 2001,
      respectively                                                           $     74,707    $     64,985
     Additional paid-in capital                                                 8,982,171       6,340,669
     Retained earnings                                                          3,738,930       3,435,792
                                                                             ------------    ------------
                                                                               12,795,808       9,841,446
     Less 43,910 shares of treasury stock, at cost                               (106,032)       (106,032)
                                                                             ------------    ------------
     Total Shareholders' Equity                                                12,689,776       9,735,414
                                                                             ------------    ------------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY                                   $ 16,360,475    $ 14,431,343
                                                                             ============    ============

</TABLE>

See accompanying notes to condensed financial statements.

       *  Derived from audited financial statements,  with  reclassifications to
          conform to September 30, 2002 presentation.


                                      -3-
<PAGE>

                  AMERICAN MEDICAL ALERT CORP. AND SUBSIDIARIES

                   CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                                   (Unaudited)

<TABLE>
<CAPTION>

                                                                Nine Months Ended September 30,
                                                                -------------------------------
                                                                      2002            2001
                                                                      ----            ----
<S>                                                              <C>             <C>
Revenues:
       Services                                                  $ 10,780,348    $  9,994,821
       Product sales                                                  234,521         267,921
                                                                      -------         -------
                                                                   11,014,869      10,262,742
                                                                 ------------    ------------
Costs and Expenses (Income):
       Costs related to services                                    5,052,523       4,963,588
       Costs of products sold                                         129,429         168,522
       Selling, general and administrative expenses                 5,492,509       4,829,944
       Interest expense                                                96,386         174,418
       Other income                                                  (333,116)        (81,693)
                                                                 ------------    ------------
                                                                   10,437,731      10,054,779
                                                                 ------------    ------------

Income before Provision for Income Taxes                              577,138         207,963

       Provision for Income Taxes                                     274,000          89,738
                                                                 ------------    ------------

NET INCOME                                                       $    303,138    $    118,225
                                                                 ============    ============
Net Income per Share:
       Basic                                                     $        .04    $        .02
                                                                 ------------    ------------
       Diluted                                                   $        .04    $        .02
                                                                 ------------    ------------
Weighted average number of common shares outstanding (Note 3):

       Basic                                                        7,108,812       6,427,303
                                                                 ============    ============
       Diluted                                                      7,562,729       6,573,775
                                                                 ============    ============

</TABLE>

See accompanying notes to condensed financial statements.


                                      -4-
<PAGE>

                  AMERICAN MEDICAL ALERT CORP. AND SUBSIDIARIES

                   CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                                   (Unaudited)

<TABLE>
<CAPTION>

                                                           Three Months Ended September 30,
                                                           --------------------------------
                                                                      2002          2001
                                                                      ----          ----
<S>                                                              <C>            <C>
Revenues:
       Services                                                  $ 3,637,613    $ 3,451,025
       Product sales                                                 114,034         66,769
                                                                 -----------    -----------
                                                                   3,751,647      3,517,794
                                                                 -----------    -----------
Costs and Expenses (Income):
       Costs related to services                                   1,733,670      1,706,621
       Costs of products sold                                         66,184         43,885
       Selling, general and administrative expenses                1,944,303      1,551,881
       Interest expense                                               25,929         52,847
       Other income                                                 (161,562)       (23,365)
                                                                 -----------    -----------
                                                                   3,608,524      3,331,869
                                                                 -----------    -----------

Income before Provision for Income Taxes                             143,123        185,925

        Provision for Income Taxes                                    59,000         79,705
                                                                 -----------    -----------

NET INCOME                                                       $    84,123    $   106,220
                                                                 ===========    ===========
Net Income per Share
        Basic                                                    $       .01    $       .02
                                                                 -----------    -----------
        Diluted                                                  $       .01    $       .02
                                                                 -----------    -----------

Weighted average number of common shares outstanding (Note 3):
        Basic                                                      7,426,739      6,449,186
                                                                 -----------    -----------
        Diluted                                                    7,796,499      6,520,644
                                                                 -----------    -----------

</TABLE>

See accompanying notes to condensed financial statements.


                                      -5-
<PAGE>

                  AMERICAN MEDICAL ALERT CORP. AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (Unaudited)

<TABLE>
<CAPTION>

                                                                    Nine Months Ended September 30,
                                                                    ------------------------------
                                                                                2002           2001*
                                                                                ----           ----
<S>                                                                        <C>            <C>
Cash Flows from Operating Activities:
     Net income                                                            $   303,138    $   118,225
     Adjustments to reconcile net income to
       net cash provided by operating activities
      Depreciation and amortization                                          1,504,512      1,492,059
      Valuation of put warrants                                                 90,000         60,000
      Accrued interest income                                                  (46,827)           -
      Decrease (increase) in:
        Accounts receivable                                                   (159,513)       (59,948)
        Inventory                                                               (5,078)       (52,189)
        Prepaid and refundable taxes                                            21,547        165,163
        Prepaid expenses and other current assets                             (141,320)       (70,342)
        Other assets                                                           (51,044)           -
      (Decrease) in:
        Accounts payable, accrued expenses and other                          (380,340)      (316,840)
        Deferred revenue                                                       (51,341)      (105,534)
                                                                           -----------    -----------

Net Cash Provided by Operating Activities                                    1,083,734      1,230,594
                                                                           -----------    -----------
Cash Flows from Investing Activities:
        Expenditures for fixed assets                                         (571,838)      (463,143)
        Investment in marketable securities                                 (2,041,929)           -
        Deposit applied on medical devices                                      20,355            -
        Increase in notes receivable                                               -         (140,000)
        Repayment of notes receivable                                          196,895         78,589
        Payment for goodwill, account acquisitions, licensing agreements
         and deferred charges                                                 (440,803)       (97,848)
                                                                           -----------    -----------

Net Cash (Used In) Investing Activities                                     (2,837,320)      (622,402)
                                                                           -----------    -----------
Cash Flows from Financing Activities:
        Proceeds from debt                                                   1,787,054         17,898
        Principal payments under capital lease obligation                     (157,654)      (141,373)
        Repayment of notes payable                                          (2,266,121)      (405,454)
        Proceeds from private equity placement                               2,730,000            -
        Payment of fees relating to private equity placement                  (208,061)           -
        Net proceeds upon exercise of stock options                            129,284         67,647
                                                                           -----------    -----------
Net Cash Provided by (Used In) Financing Activities                          2,014,502       (461,282)
                                                                           -----------    -----------

Net Increase in Cash and Cash Equivalents                                      260,916        146,910
Cash and Cash Equivalents, Beginning of Period                                 818,696        537,247
                                                                           -----------    -----------
Cash and Cash Equivalents, End of Period                                   $ 1,079,612    $   684,157
                                                                           ===========    ===========

</TABLE>

See accompanying notes to condensed financial statements.


                                      -6-
<PAGE>

<TABLE>
<CAPTION>

<S>                                                                        <C>            <C>
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for:
          Interest                                                         $    90,980    $    169,031
          Income Taxes                                                     $   253,410    $    149,306

</TABLE>

SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND
FINANCING ACTIVITY:

During 2001 the Company  incurred  capital lease  obligations of
$98,340 when it entered into a lease agreement for new equipment.

See accompanying notes to condensed financial statements

 * Reclassified to conform with September 30, 2002 presentation


                                      -7-
<PAGE>

                  AMERICAN MEDICAL ALERT CORP. AND SUBSIDIARIES
              Notes to Condensed Consolidated Financial Statements
                                   (Unaudited)

1.   General:

     These financial statements should be read in conjunction with the financial
statements  and notes  thereto for the year ended  December 31, 2001 included in
the Company's Annual Report on Form 10-KSB.

2.   Results of Operations:

     In  the  opinion  of  management,   the  accompanying  unaudited  condensed
financial  statements  contain  all  adjustments   (consisting  only  of  normal
recurring  accruals)  necessary to present  fairly the financial  position as of
September 30, 2002,  and the results of operations for the nine and three months
ended  September  30, 2002 and 2001,  and cash flows for the nine  months  ended
September 30, 2002 and 2001.

     The accounting  policies used in preparing these  financial  statements are
the same as those  described  in the  December  31, 2001  financial  statements,
except as described in Note 3 below.  In addition,  effective June 30, 2002, the
amounts  previously  reported as "Inventory  of medical  devices held for lease"
have been reclassified as a component of fixed assets.

     The Company accounts for its marketable securities,  consisting of a mutual
fund, in accordance with Statement of Financial  Accounting  Standards  ("SFAS")
No. 115 "Accounting for Certain Investments in Debt and Equity  Securities".  In
accordance  with  the  provisions  of SFAS No.  115,  the  Company's  marketable
securities are  classified as securities  available for sale and are reported at
their approximate fair value. Although not a money market fund, this mutual fund
seeks to generate  returns in excess of traditional  money market products while
maintaining an emphasis on preservation  of capital and liquidity.  At September
30, 2002 the cost of the marketable securities equaled the fair value.

     The results of operations for the nine and three months ended September 30,
2002 and 2001 are not  necessarily  indicative of the results to be expected for
any other interim period or for the full year.

3.   New Pronouncements

     In June 2001, the Financial  Accounting  Standards Board (FASB) issued SFAS
No. 142,  "Goodwill and Other Intangible  Assets" which states that goodwill and
other  intangible  assets with indefinite  lives, are no longer to be amortized,
but instead are to be tested for  impairment at least  annually.  The impairment
process  consists of  comparing  the fair value of the  intangible  asset to its
carrying value. The Company adopted SFAS No. 142 effective January 1, 2002.


                                      -8-
<PAGE>

The financial information for acquired intangible assets is as follows:

<TABLE>
<CAPTION>

                                  As of September 30, 2002              As of December 31, 2001
                                  ------------------------              -----------------------
                              Gross Carrying     Accumulated        Gross Carrying      Accumulated
                                  Amount         Amortization           Amount          Amortization
                                  ------         ------------           ------          ------------
<S>                            <C>                <C>                <C>                <C>
Amortized intangible assets
  Account acquisitions         $  879,443         $  511,126         $  859,048         $  374,983
  Noncompete agreement             60,000             26,250             60,000             15,000
  Deferred charges                 77,750              3,887             41,022              8,204
  Licensing fees                  446,960                -              195,335                -
                               ----------         ----------         ----------         ----------
     Total                     $1,464,153         $  541,263         $1,155,405         $  398,187

</TABLE>

Amortization  expense for the nine and three months ended September 30, 2002 was
approximately   $184,000  and  $53,000,   respectively,   and  annual  estimated
amortization,  based on the current amount of intangible  assets,  is as follows
(exclusive of the  intangible  assets  relating to the Company's  agreement with
Health Hero Network, Inc.):

Estimated amortization expense:
------------------------------

   For the year ended December 31, 2002                                $ 237,000
   For the year ended December 31, 2003                                $ 180,000
   For the year ended December 31, 2004                                $ 161,000
   For the year ended December 31, 2005                                $  44,000
   For the year ended December 31, 2006                                $  20,000

The changes in carrying amount of goodwill for the nine months ended September
30, 2002 are as follows:

<TABLE>
<CAPTION>

                                         PERS        TAS       Other   Consolidated
                                        ------     --------    -----   ------------
<S>                                    <C>        <C>          <C>        <C>
Balance as of December 31, 2001        $    -     $ 837,504    $    -     $ 837,504

Additional Goodwill                         -        91,033         -        91,033

Balance as of September 30, 2002       $    -     $ 928,537    $    -     $ 928,537

</TABLE>

The following financial information is presented as if SFAS 142 was adopted at
the beginning of the nine months ended September 30, 2001:

                                         For the nine months ended September 30,
                                         ---------------------------------------
                                                2002                2001
                                                ----                ----
Net Income:
 Reported net income                      $    303,138           $     118,225


                                      -9-

<PAGE>

 Add back: Goodwill amortization                   -                    40,167
 Adjusted net income                      $    303,138           $     158,392

Basic earnings per share:
 Reported basic earnings per share        $        .04           $         .02
 Add back: Goodwill amortization                   -                       -
 Adjusted basic earnings per share        $        .04           $         .02

Diluted earnings per share:
 Reported diluted earnings per share      $        .04           $        .02
 Add back: Goodwill amortization                   -                       -
 Adjusted diluted earnings per share      $        .04           $        .02

                                        For the three months ended September 30,
                                        ----------------------------------------
                                                2002                2001
                                                ----                ----
Net Income:
  Reported net income                     $    84,123            $     106,220
  Add back: Goodwill amortization                 -                     13,741
  Adjusted net income                     $    84,123            $     119,961

Basic earnings per share:
  Reported basic earnings per share       $       .01            $         .02
  Add back: Goodwill amortization                 -                        -
  Adjusted basic earnings per share       $       .01            $         .02

Diluted earnings per share:
  Reported diluted earnings per share     $       .01            $         .02
  Add back: Goodwill amortization                 -                        -
  Adjusted diluted earnings per share     $       .01            $         .02

In August 2001, the FASB issued SFAS No. 144  "Accounting  for the Impairment or
Disposal of Long Lived Assets".  This statement supersedes SFAS 121, "Accounting
for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed
Of", while retaining many of the  requirements  of such  statement.  The Company
adopted SFAS No. 144 effective  January 1, 2002. The  application did not have a
significant   impact  on  the  Company's  results  of  operations  or  financial
condition.

                                      -10-
<PAGE>

4.   Earnings Per Share

     The following table is a reconciliation  of the numerators and denominators
in computing earnings per share:

<TABLE>
<CAPTION>

                                                             Income                Shares               Per-Share
Nine Months Ended September 30, 2002                      (Numerator)           (Denominator)            Amounts
------------------------------------                      -----------           -------------            -------
<S>                                                           <C>                      <C>                 <C>
Basic EPS -
Income available to common
stockholders                                                  $  303,138               7,108,812           $.04
Effect of dilutive securities -                                                                            ====
 Options and warrants                                                -0-                 453,917
                                                              ----------               ---------
Diluted EPS -
Income available to common
 stockholders and assumed conversions                         $  303,138               7,562,729           $.04
                                                              ==========               =========           ====
Three Months Ended September 30, 2002
-------------------------------------
Basic EPS - Income available to
 common stockholders                                          $   84,123               7,426,739           $.01
Effect of dilutive securities -                                                                            ====
  Options and warrants                                               -0-                 369,760
                                                              ----------               ---------
Diluted EPS - Income available to
 common stockholders and assumed
 conversions                                                  $   84,123               7,796,499           $.01
                                                              ==========               =========           ====
Nine Months Ended September 30, 2001
------------------------------------
Basic EPS -Income available to common
 stockholders                                                 $  118,225               6,427,303           $.02
                                                              ==========               =========           ====
Effect of dilutive securities -
 Options and warrants                                                -0-                 146,472
                                                              ----------               ---------
Diluted EPS -Income available to
 common stockholders and
 assumed conversions                                          $  118,225               6,573,775           $.02
                                                              ==========               =========           ====
Three Months Ended September 30, 2001
-------------------------------------
Basic EPS - Income available to
 common stockholders                                          $  106,220               6,449,186           $.02
Effect of dilutive securities -                                                                            ====
 Options and warrants                                                -0-                  71,458
                                                              ----------               ---------
Diluted EPS -Income available to
 common stockholders and assumed
 conversions                                                  $  106,220               6,520,644           $.02
                                                              ==========               =========           ====

</TABLE>


                                      -11-
<PAGE>

5.   Notes Payable:

     In May 2002,  the Company  executed an agreement  with a bank,  pursuant to
which it received a credit facility of $3,000,000, which includes a term loan of
$1,500,000  and a revolving  credit line that permits  maximum  borrowings up to
$1,500,000 (based on eligible receivables as defined). Borrowings under the term
loan will bear  interest at LIBOR plus 3.5% and  borrowings  under the revolving
credit line will bear interest at LIBOR plus 3.0%. The term loan is payable over
five years while the credit  facility is available for three years.  The Company
used a portion of the  proceeds to repay the  previous  bank debt and intends to
use the remaining proceeds from this bank financing to fund capital expenditures
and working capital needs.

6.   Private Equity Placement:

     In April 2002, the Company raised  $2,521,939,  after expenses of $208,061,
in a private  equity  placement  of the  Company's  common  stock and  warrants.
Several  investors  purchased an aggregate  of 910,000  shares of the  Company's
common stock and warrants to purchase  227,500  shares of the  Company's  common
stock at an exercise price of $3.80 per share. As part of this transaction,  the
Company  registered for resale the common stock and the common stock  underlying
the  warrants  sold in the private  placement.  The  Company  plans to utilize a
majority of the  proceeds  of this  offering  to further  execute  its  business
expansion and  diversification  strategy into the remote patient  monitoring and
medical contact center industries,  including its recently announced  initiative
with Health Hero Network, Inc. ("HHN").

7.   Major Customers:

     Since  1983,  the  Company has  provided  PERS  services to the City of New
York's Human Resources  Administration  Home Care Service Program ("HCSP").  The
Company provides services to the City of New York under extensions and contracts
issued  periodically.  The current  contract runs through June 2003 and reflects
terms and conditions present in the original contract. On October 10, 2002, HCSP
issued a Request For Proposal ("RFP") to provide continued services,  after June
30, 2003, to subscribers currently serviced under the PERS contract. The Company
intends to respond to this bid and plans to make its best reasonable  efforts to
be awarded and maintain this contract. During the nine months September 30, 2002
and 2001, the Company had revenues from this contract  representing 24% and 26%,
respectively, of its total revenue.

If as a result of the RFP dated  October  10,  2002,  the Company is awarded the
contract,  there can be no  assurance  that the same level of  revenues  will be
sustained due to a variety of factors,  including pricing, number of subscribers
to be serviced,  and the amount of time that passes before the RFP is acted upon
by HCSP.  While the Company has reduced its  dependence  on revenue from HCSP, a
significant  amount  of the  Company's  revenue  could  be lost,  albeit  over a
protracted  period, if the contract with HCSP is not awarded or is maintained at
a  significantly  lower  level of  revenue.  This could have a material  adverse
effect on operating  results and cash flows.  In addition,  it is possible  that
significant adjustments to medical devices included in fixed assets would occur.
The extent and significance of the adjustments will be dependent upon the length
of the transition period, if the contract is awarded to a new provider, or, even
if the


                                      -12-
<PAGE>

Company is awarded the contract, on the significance of any reduction in pricing
or  number  of  subscribers  serviced.  These  factors  could  be  mitigated  by
management's ability to place these devices with other providers.

     As of September 30, 2002 and December 31, 2001,  accounts  receivable  from
the contract represented 49% and 47%,  respectively,  of accounts receivable and
leased medical  devices in service under the contract  represented  24% and 30%,
respectively, of total leased medical devices in service.

8.   Segment Reporting:

The Company has two reportable  segments,  Personal  Emergency  Response Systems
("PERS") and Telephone After-Hours Answering Service ("TAS"),  which is provided
through the  Company's  HCI  subsidiary,  which  acquired  the assets of Harriet
Campbell Inc. on November 21, 2000.

The table  below  provides  a  reconciliation  of segment  information  to total
consolidated  information for the nine and three months ended September 30, 2002
and 2001:

<TABLE>
<CAPTION>

                                                              2002
                                                              ----

                                                           PERS              TAS              Other        Consolidated
                                                       ------------     ------------      ------------     ------------
Nine Months Ended September 30, 2002
------------------------------------
<S>                                                    <C>              <C>               <C>              <C>
Revenue                                                $  8,988,425     $  1,904,124      $    122,320     $11,014,869
Income (loss) before provision for
income taxes                                                286,759          295,352            (4,973)        577,138
Total assets                                             13,847,601        2,288,150           224,724      16,360,475

                                                           PERS              TAS              Other        Consolidated
                                                       ------------     ------------      ------------     ------------
Three Months Ended September 30, 2002
-------------------------------------
Revenue                                                $  3,028,969     $    675,407      $     47,271     $  3,751,647
Income (loss) before provision for
income taxes                                                 41,146          108,210            (6,233)         143,123

<CAPTION>

                                                              2001
                                                              ----

                                                           PERS              TAS              Other        Consolidated
                                                       ------------     ------------      ------------     ------------
<S>                                                    <C>              <C>               <C>              <C>
Nine Months Ended September 30, 2001
------------------------------------
Revenue                                                $  8,503,620     $  1,692,624      $     66,498     $ 10,262,742
Income (loss) before provision for
income taxes                                                 30,706          208,964           (31,707)         207,963
Total assets                                             12,471,935        1,889,301           165,506       14,526,742

</TABLE>


                                      -13-
<PAGE>

<TABLE>
<CAPTION>

                                                           PERS              TAS              Other        Consolidated
                                                       ------------     ------------      ------------     ------------
<S>                                                    <C>              <C>               <C>              <C>
Three Months Ended September 30, 2001
-------------------------------------
Revenue                                                $  2,879,482     $    613,659      $     24,653     $  3,517,794
Income (loss) before provision for
income taxes                                                 94,137          103,820           (12,032)         185,925

</TABLE>

9.   Contingencies:

     Although the Company is a party to certain routine litigation incidental to
its business, the Company believes that, except as set forth below, there are no
material pending legal proceedings to which it is a party or to which any of its
properties are subject.

     On March 2, 2001 American Medical Alert Corp. was served with a Summons and
Complaint by a former employee seeking to recover damages for discrimination and
harassment in connection  with her  employment  and the  associated  termination
thereof.  The action is  pending  in the  Supreme  Court of Queens  County.  The
plaintiff  seeks to recover the sum of  $750,000  for  compensatory  damages and
$750,000  for  punitive  damages.  At this stage of the  proceedings,  it is not
possible to predict the outcome of this litigation, however, management believes
that the Company has meritorious defenses to the complaint.  At the present time
the  insurance  company  has  declined  coverage  although  efforts  to obtain a
reversal of the declination of coverage are ongoing.

ITEM 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        ------------------------------------------------------------------------
OF OPERATIONS.
-------------

The following  discussion and analysis  provides  information  which  management
believes is relevant to an assessment and understanding of the Company's results
of  operations  and  financial  condition.  The  discussion  should  be  read in
conjunction with the consolidated  financial  statements contained in the latest
Annual Report dated December 31, 2001.

This  discussion  contains  forward-looking  statements  which,  in  addition to
assuming a  continuation  of the degree and timing of customer  utilization  and
rate of renewals of contracts with the Company at historical levels, are subject
to a number of known and unknown  risks that,  in addition to general  economic,
competitive  and  other  business   conditions,   could  cause  actual  results,
performance  and  achievements  to differ  materially  from those  described  or
implied  in  the  forward-looking  statements.  The  risk  factors  are  further
discussed with the Company's filings with the Securities Exchange Commission.


                                      -14-
<PAGE>

LIQUIDITY AND CAPITAL RESOURCES
-------------------------------

In April 2002, the Company raised $2,521,939,  after expenses of $208,061,  in a
private  equity  placement of the Company's  common stock and warrants.  Several
investors purchased an aggregate of 910,000 shares of the Company's common stock
and  warrants to purchase  227,500  shares of the  Company's  common stock at an
exercise  price of $3.80 per share.  As part of this  transaction,  the  Company
registered  for resale the common  stock and the  common  stock  underlying  the
warrants sold in the private placement.  The Company plans to utilize a majority
of the proceeds of this offering to further  execute its business  expansion and
diversification  strategy into the remote patient monitoring and medical contact
center industries, including its recently announced initiative with HHN.

In May 2002, the Company executed an agreement with a bank, pursuant to which it
received  a  credit  facility  of  $3,000,000,  which  includes  a term  loan of
$1,500,000  and a revolving  credit line that permits  maximum  borrowings up to
$1,500,000 (based on eligible receivables as defined). Borrowings under the term
loan will bear  interest at LIBOR plus 3.5% and  borrowings  under the revolving
credit line will bear interest at LIBOR plus 3.0%. The term loan is payable over
five years while the credit  facility is available for three years.  The Company
used a portion of the  proceeds to repay the  previous  bank debt and intends to
use the remaining proceeds from this bank financing to fund capital expenditures
and working capital needs.

The following table is a summary of contractual  obligations as of September 30,
2002:

<TABLE>
<CAPTION>

----------------------------------------------------------------------------------------------------------------------
                                                                 Payments Due by Period
----------------------------------------------------------------------------------------------------------------------
Contractual  Obligations            Total           Less  than  1   1-3 years       4-5 years      After 5 years
                                                    year
----------------------------------------------------------------------------------------------------------------------
<S>                                 <C>             <C>             <C>             <C>
Revolving Credit Line               $   -0-         $     -
----------------------------------------------------------------------------------------------------------------------
Debt                                $1,466,121      $   314,917     $  926,204      $ 225,000
----------------------------------------------------------------------------------------------------------------------
Capital Leases                      $  237,314      $   182,588     $   54,726
----------------------------------------------------------------------------------------------------------------------
Operating Leases                    $1,259,508      $   287,383     $  727,718      $ 244,407
----------------------------------------------------------------------------------------------------------------------
Total Contractual Cash              $2,962,943      $   784,888     $1,708,648      $ 469,407
Obligations
----------------------------------------------------------------------------------------------------------------------

</TABLE>

The Company's  working  capital on September 30, 2002 was $5,848,361 as compared
to $1,757,078 on December 31, 2001.  The Company  believes that its present cash
and working capital position combined with its borrowing  availability under its
new credit facility and future  anticipated  cash flow generated from operations
will be sufficient  to meet its cash and working  capital needs for at least the
next 12 months.  During 2002, the Company  anticipates that it will make capital
investments  of  approximately  $1,250,000,  exclusive  of  capital  investments
relating  to the  Company's  agreement  with  HHN,  for the  enhancement  of its
management  information


                                      -15-
<PAGE>

systems,  and the production  and purchase of additional  PERS which the Company
intends to rent.

On January 14, 2002, the Company  entered into an operating  lease agreement for
space  in Long  Island  City,  New York in an  effort  to  consolidate  its HCI,
Flushing and Oceanside ERC and Customer Service facilities. The Company believes
that  centralization  of the ERC,  Customer Service and H-Link OnCall operations
would provide  additional  efficiencies  and facilitate the continued  projected
growth of the H-Link and Disease Management  Monitoring  divisions.  The term of
the lease is fifteen (15) years from the  commencement  date.  The  commencement
date is the last of the following to occur: (a) the date on which landlord gives
notice  to  tenant  that  the  work  to  be   performed  by  landlord  has  been
substantially  completed;  (b) the date landlord shall have obtained a temporary
certificate  of occupancy  for the  building  which  authorizes  and permits the
occupancy  by tenant;  and (c) the date on which the certain  interior  work has
been completed. The lease calls for minimum annual rentals of $269,500,  subject
to a 3% annual increase plus reimbursement for real estate taxes. As a result of
this  transaction,  the Company and the building  are  eligible for  significant
Relocation and Employment  Assistance Program (REAP) and other tax incentive and
cost savings  benefits from the City of New York. The Company  expects to occupy
the premises during the first quarter of 2003. Simultaneously with the move, the
Company  plans to  consolidate  certain  facilities  and  sell  the  condominium
currently occupied by HCI Acquisition Corp.

On  November  1,  2001,  the  Company  entered  into  a  Cooperative  Licensing,
Development,  Services and Marketing  Agreement  with HHN (the "HHN  Agreement")
pursuant to which the Company is  developing,  with the assistance of HHN, a new
integrated  appliance  combining the features of the Company's PERS product with
HHN's  technology.  Pursuant  to the  HHN  Agreement,  the  Company  will be the
exclusive  manufacturer  and distributor  (based on achievement of certain sales
milestones),  in the United States, of an enhanced PERS system that combines the
Company's  traditional  safety  monitoring  features with HHN's  internet  based
disease  management  monitoring  technology.  The HHN  Agreement  has a  minimum
five-year term, and also provides for the payment by the Company of certain fees
based on the service revenue derived from the enhanced PERS product. The Company
anticipates the costs  associated  with the licensing,  research and development
and marketing with respect to the HHN Agreement to approximate  $2,000,000  over
the next  12-18  months.  The cost of the  licensing  component  will  aggregate
$1,000,000,  of which  approximately  $300,000  has been paid as of  November 9,
2002.  Related  professional  fees of  $145,000  have been  capitalized  through
September 30, 2002.

As part of executing its business plan to align itself for future  success,  the
Company has incurred and plans to incur certain additional  expenses relating to
the  relocation  and upgrading of its  emergency  response  center  facility and
research and development costs associated with its disease management  endeavor.
As a result  of these  expenses,  the  profitability  for the next  three to six
months may be impacted.  As the Company  continues to diversify,  enter into new
endeavors  and execute its business  plan,  the Company  continues to affirm its
positive  outlook  and  anticipates   achieving  gross  sales  of  approximately
$15,000,000 and net income of $350,000-$400,000  for the year ended December 31,
2002.


                                      -16-
<PAGE>

The Company has become aware that certain of its activators designed to remotely
signal the emergency  response  apparatus  installed in a client's  home, may be
subject  to  battery  failure,  thereby  preventing  remote  activation  of  the
apparatus and requiring  the consumer to activate the  apparatus  directly.  The
supplier of the activators has  acknowledged its  responsibility  to replace the
activators,  and thus, the Company  should not incur any financial  liability in
exchanging the activators for upgraded models, which is currently in process. No
claim for  liability  has been  asserted  against the Company  arising from this
situation, but such a claim is possible.

Since 1983,  the Company has  provided  PERS  services to the City of New York's
Human Resources  Administration Home Care Service Program ("HCSP").  The Company
provides  services to the City of New York under extensions and contracts issued
periodically.  The current  contract,  runs  through  June 2003 and reflects the
terms and conditions present in the original contract.  On October 10, 2002, HRA
issued a Request For Proposal ("RFP") to provide continued services,  after June
30, 2003, to subscribers currently serviced under the PERS contract. The Company
intends to respond to this bid and plans to make its best reasonable  efforts to
be awarded and maintain this  contract.  During the nine months ended  September
30, 2002 and 2001, the Company had revenues from this contract  representing 24%
and 26%, respectively, of its total revenue.

If as a result of the RFP dated  October  10,  2002,  the Company is awarded the
contract,  there can be no  assurance  that the same level of  revenues  will be
sustained due to a variety of factors,  including pricing, number of subscribers
to be serviced,  and the amount of time that passes before the RFP is acted upon
by HCSP.  While the Company has reduced its  dependence  on revenue from HCSP, a
significant  amount  of the  Company's  revenue  could  be lost,  albeit  over a
protracted  period, if the contract with HCSP is not awarded or is maintained at
a  significantly  lower  level of  revenue.  This could have a material  adverse
effect on operating  results and cash flows.  In addition,  it is possible  that
significant adjustments to medical devices included in fixed assets would occur.
The extent and significance of the adjustments will be dependent upon the length
of the transition period, if the contract is awarded to a new provider, or, even
if the Company is awarded the contract,  on the significance of any reduction in
the pricing or number of subscribers serviced.  These factors could be mitigated
by management's ability to place these devices with other providers.

The Company's  management has developed a business plan to minimize its reliance
on HCSP. This involves the reduction in HCSP related  overhead and  redeployment
of assets to other  programs,  in the event that the HCSP  contract  were not to
continue  for any reason.  In addition,  the Company  focuses on, and intends to
continue to build its subscriber base through,  consumers,  healthcare agencies,
health   maintenance   organizations,   durable  medical  equipment   providers,
retirement communities,  hospitals and other governmental agencies. In addition,
the Company is continuing to invest in new products, services, and initiatives.

RESULTS OF OPERATIONS
---------------------

Monthly recurring  revenue for services ("MRR") increased  $785,527 for the nine
months  ended  September  30, 2002 as  compared  to the same period in 2001,  an
increase of 8%, and increased


                                      -17-
<PAGE>

$186,588 for the three months ended  September  30, 2002 as compared to the same
period in 2001, an increase of 5%. The Company has experienced continued success
in growing its  customer  base  outside the  contract  with the City of New York
(which has  experienced  a reduction in the number of  subscribers  and revenue)
through a variety of marketing  efforts that have  continued  to  contribute  to
increasing  MRR. These efforts include  expansion into new regions,  competitive
conversions,  strategic  partnerships  with  healthcare  provider  systems,  and
additional entry into Medicaid reimbursed marketplaces. In addition, the Company
has  experienced  growth in its  OnCall  telephone  answering  service  business
through its marketing efforts, which includes the execution of an agreement with
Broadlane.

Costs  related to  services  increased  by  $88,935  for the nine  months  ended
September 30, 2002 as compared to the same period in 2001, an increase of 2% and
increased  $27,049 for the three months ended  September 30, 2002 as compared to
the same period in 2001,  an increase of 2%.  Costs  related to  services,  as a
percentage of service revenues, for the nine months ended September 30, 2002 and
2001  were 47% and  50%,  respectively.  The  costs  related  to  services  as a
percentage  of service  revenue  decreased  as a result of the costs of services
remaining  consistent  with  prior  periods  as certain  increases  in  payroll,
telephone  and other  related  items were offset by a reduction in upgrading and
repair expense, while revenues increased.

Selling,  general and administrative expenses increased by $662,565 for the nine
months  ended  September  30, 2002 as  compared  to the same period in 2001,  an
increase of 14%. Selling,  general,  and administrative  expenses expressed as a
percentage  of total  revenues was 50% and 47% for each of the nine months ended
September 30, 2002 and 2001,  respectively.  Selling, general and administrative
expenses  increased by $392,422 for the three months ended September 30, 2002 as
compared to the same period in 2001, an increase of 25%. Selling,  general,  and
administrative  expenses  expressed  as a percentage  of total  revenues for the
three months ended  September 30, 2002 and 2001 were 52% and 44%,  respectively.
The dollar increase in selling,  general and  administrative  expenses is due to
increased  commissions,  the  hiring  of  independent  consultants  to assist in
advisory  matters and  increased  bad debt  expense,  offset by a  reduction  in
professional fees. Additionally, an increase of approximately $300,000 is due to
the  hiring  of  personnel  and  incurring   research  and   development   costs
specifically  relating to the HHN endeavor.  Also,  certain  internal costs have
been incurred with regard to the  replacement of activiators  that were recorded
in selling, general and administrative expenses. The Company is being reimbursed
for these costs from the supplier and this  reimbursement  is being  recorded as
other income.

Interest  expense  for the nine  months  ended  September  30, 2002 and 2001 was
$96,386 and $174,418, respectively.  Interest expense for the three months ended
September  30,  2002 and 2001 was $25,929 and  $52,847,  respectively.  Interest
expense  decreased  due to reduction of borrowing  levels during 2002 as well as
the decrease in interest rates.

Other income for the nine months ended  September 30, 2002 and 2001 was $333,116
and $81,693, respectively. Other income for the three months ended September 30,
2002 and 2001 was $161,562 and 23,365, respectively.  Other income increased due
to an insurance  reimbursement,  income earned due to  replacement of activators
and interest  recorded on an officer's loan. The Company records as Other Income
funds  received  from the supplier to reimburse  for costs  associated  with the
replacement  of  activators.  The  direct  costs paid to third


                                      -18-
<PAGE>

parties for the  replacement  of these  activators is offset  against this Other
Income and the  internal  costs are  charged to  expense.  The  interest  on the
officer's loan was approximately $47,000 on this officer's loan.

The Company's income before provision for income taxes for the nine months ended
September  30,  2002 was  $577,138,  an  increase  of  $369,175  from 2001.  The
Company's  income  before  provision for income taxes for the three months ended
September 30, 2002 was $143,123 a decrease of $42,802 from 2001. The increase in
profit of  $369,175  for the nine months  ended  September  30,  2002  primarily
resulted from an increase in the Company's  revenues from services,  an increase
in other income (an insurance reimbursement) and a decrease in interest expense,
offset by an increase in selling, general and administrative costs.

ITEM 3. CONTROLS AND PROCEDURES.
        ------------------------

Evaluation of Disclosure Controls and Procedures

Within 90 days prior to the date of this  report,  the  Company  carried  out an
evaluation,  under the supervision and with the  participation  of the Company's
management,  including the Company's President and Chief Executive Officer along
with the Company's  Principal  Financial Officer, as to the effectiveness of the
design and operation of the Company's  "disclosure  controls and procedures" (as
defined  in  Exchange  Act  Rules  13a-14(c)  and  15d-14(c)).   Based  on  this
evaluation,  the President and Chief Executive  Officer along with the Principal
Financial  Officer have  concluded  that the Company's  disclosure  controls and
procedures were effective.

Changes in Internal Controls

There were no significant changes in the Company's internal controls,  or to the
Company's  knowledge,  in other  factors  that  could  significantly  affect the
Company's disclosure controls and procedures subsequent to November 8, 2002.

                           PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.
        ------------------

Although the Company is a party to certain routine litigation  incidental to its
business,  the Company  believes that,  except as set forth below,  there are no
material pending legal proceedings to which it is a party or to which any of its
properties are subject.

On March 2, 2001  American  Medical  Alert  Corp.  was served with a Summons and
Complaint by a former employee seeking to recover damages for discrimination and
harassment  in  connection  with  her  employment  and the  alleged  termination
thereof.  The action is  pending  in the  Supreme  Court of Queens  County.  The
plaintiff  seeks to recover the sum of  $750,000  for  compensatory  damages and
$750,000 for punitive  damages.  Based on the facts known to them, the attorneys
representing   the  Company  believe  that  American  Medical  Alert  Corp.  has
meritorious  defenses  to the  complaint.  At the  present  time  the  Company's
insurance company has declined coverage although efforts to obtain a reversal of
the declination of coverage are ongoing.


                                      -19-
<PAGE>

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
        ---------------------------------------------------

     On  August  13,  2002,   the  Company  held  its  2002  Annual  Meeting  of
Shareholders (the "2002 Meeting").

     At the 2002 Meeting,  the Company's  shareholders (i) elected six directors
to serve  until  the  2002  Annual  Meeting  of  Shareholders  and  until  their
successors  shall be elected and  qualified,  (ii)  approved on amendment to the
Company's  Articles of Incorporation to provide for a general purposes clause in
place of the existing  purposes  clause,  and (iii)  ratified  the  selection of
Margolin, Winer & Evens LLP as the Company's independent auditors for the fiscal
year ending December 31, 2002.

1.   The vote with respect to the election of directors was as follows:

               NAME                      FOR                  AUTHORITY WITHHELD
               ----                      ---                  ------------------

(a)      Howard M. Siegel              5,808,407                     37,100
(b)      James LaPolla                 5,810,407                     35,100
(c)      Frederick Siegel              5,808,407                     37,100
(d)      Ronald Levin                  5,810,907                     34,600
(e)      Yacov Shamash                 5,810,407                     35,100
(f)      Delphine Mendez-de Leon       5,810,407                     35,100

2.   The proposal to amend the Company's  Articles of  Incorporation  to provide
     for a general purposes clause in place of the existing purposes clause, was
     approved by the following vote:

              For                   Against                       Abstain
              ---                   -------                       -------
           5,800,007                41,000                        4,500

3.   The proposal to ratify the selection of Margolin,  Winer & Evens LLP as the
     Company's  independent  auditors  for the fiscal year ending  December  31,
     2002, was approved by the following vote:

              For                   Against                       Abstain
              ---                   -------                       -------
           5,819,707                22,700                        3,100

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
        ---------------------------------

(a) Exhibits:

No.            Description
---            -----------

3.1            Certificate   of  Amendment  to  the  Company's   Certificate  of
               Incorporation.
99.1           Certification  of CEO  Pursuant  to Section  906 of the  Sarbanes
               Oxley Act of 2002.


                                      -20-
<PAGE>

99.2           Certification of Controller (chief financial officer) Pursuant to
               Section 906 of the Sarbanes Oxley Act of 2002.

(b) Reports on Form 8-K:

     On August 13, 2002 the Company filed a Current  Report on Form 8-K relating
to Item 9,  Regulation FD Disclosure,  reporting the issuance of a press release
announcing the Company's results for the second quarter ended June 30, 2002.






                                      -21-
<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Company  has  duly  caused  this  report  to be  signed  on  its  behalf  by the
undersigned thereunto duly authorized.


                                        AMERICAN MEDICAL ALERT CORP.


Dated: November 14, 2002
                                        By: /s/ Howard M. Siegel
                                           -------------------------------------
                                           Howard M. Siegel
                                           President and Chief Executive Officer


                                        By: /s/ Richard Rallo
                                           -------------------------------------
                                           Richard Rallo
                                           Controller (chief financial officer)


                                      -22-
<PAGE>

                 CERTIFICATION FOR QUARTERLY REPORT ON FORM 10-Q
                 -----------------------------------------------


I, Howard M. Siegel, certify that:

1.   I have reviewed this quarterly report on Form 10-Q of American Medical
     Alert Corp.;

2.   Based on my knowledge, this quarterly report does not contain any untrue
     statement of a material fact or omit to state a material fact necessary to
     make the statements made, in light of the circumstances under which such
     statements were made, not misleading with respect to the period covered by
     this quarterly report;

3.   Based on my knowledge, the financial statements, and other financial
     information included in this quarterly report, fairly present in all
     material respects the financial condition, results of operations and cash
     flows of the registrant as of, and for, the periods presented in this
     quarterly report;

4.   The registrant's other certifying officers and I are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

     a)   designed such disclosure controls and procedures to ensure that
          material information relating to the registrant, including its
          consolidated subsidiaries, is made known to us by others within those
          entities, particularly during the period in which this quarterly
          report is being prepared;

     b)   evaluated the effectiveness of the registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

     c)   presented in this quarterly report our conclusions about the
          effectiveness of the disclosure controls and procedures based on our
          evaluation as of the Evaluation Date;

5.   The registrant's other certifying officers and I have disclosed, based on
     our most recent evaluation, to the registrant's auditors and the audit
     committee of registrant's board of directors (or persons performing the
     equivalent function):

     a)   all significant deficiencies in the design or operation of internal
          controls which could adversely affect the registrant's ability to
          record, process, summarize and report financial data and have
          identified for the registrant's auditors any material weaknesses in
          internal controls; and

     b)   any fraud, whether or not material, that involves management or other
          employees who have a significant role in the registrant's internal
          controls; and

6.   The registrant's other certifying officers and I have indicated in this
     quarterly report whether or not there were significant changes in internal
     controls or in other factors that could significantly affect internal
     controls subsequent to the date of our most recent evaluation, including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.

Date: November 14 , 2002

                                        /s/ Howard M. Siegel
                                        -------------------------------------
                                        Howard M. Siegel
                                        President and Chief Executive Officer



                                      -23-
<PAGE>

                 CERTIFICATION FOR QUARTERLY REPORT ON FORM 10-Q
                 -----------------------------------------------

I, Richard Rallo, certify that:

1.   I have reviewed this quarterly report on Form 10-Q of American Medical
     Alert Corp.;

2.   Based on my knowledge, this quarterly report does not contain any untrue
     statement of a material fact or omit to state a material fact necessary to
     make the statements made, in light of the circumstances under which such
     statements were made, not misleading with respect to the period covered by
     this quarterly report;

3.   Based on my knowledge, the financial statements, and other financial
     information included in this quarterly report, fairly present in all
     material respects the financial condition, results of operations and cash
     flows of the registrant as of, and for, the periods presented in this
     quarterly report;

4.   The registrant's other certifying officers and I are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

     a)   designed such disclosure controls and procedures to ensure that
          material information relating to the registrant, including its
          consolidated subsidiaries, is made known to us by others within those
          entities, particularly during the period in which this quarterly
          report is being prepared;

     b)   evaluated the effectiveness of the registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

     c)   presented in this quarterly report our conclusions about the
          effectiveness of the disclosure controls and procedures based on our
          evaluation as of the Evaluation Date;

5.   The registrant's other certifying officers and I have disclosed, based on
     our most recent evaluation, to the registrant's auditors and the audit
     committee of registrant's board of directors (or persons performing the
     equivalent function):

     a)   all significant deficiencies in the design or operation of internal
          controls which could adversely affect the registrant's ability to
          record, process, summarize and report financial data and have
          identified for the registrant's auditors any material weaknesses in
          internal controls; and

     b)   any fraud, whether or not material, that involves management or other
          employees who have a significant role in the registrant's internal
          controls; and

6.   The registrant's other certifying officers and I have indicated in this
     quarterly report whether or not there were significant changes in internal
     controls or in other factors that could significantly affect internal
     controls subsequent to the date of our most recent evaluation, including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.

Date: November 14 , 2002
                                        /s/ Richard Rallo
                                        ----------------------------------------
                                        Richard Rallo
                                        Controller (chief financial officer)


                                      -24-

<PAGE>

                                  EXHIBIT INDEX

No.           Description
---           -----------

3.1           Certificate of Amendment to the Company's Certificate of
              Incorpration.
99.1          Certification of CEO Pursuant to Section 906 of the Sarbanes Oxley
              Act of 2002.
99.2          Certification of Controller (chief financial officer) Pursuant to
              Section 906 of the Sarbanes Oxley Act of 2002.